[
  {
    "id": 1,
    "entrez_name": "ALK",
    "entrez_id": 238,
    "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.",
    "clinical_description": null,
    "variants": [
      {
        "name": "R1275Q",
        "id": 9
      },
      {
        "name": "F1174L",
        "id": 8
      },
      {
        "name": "EML4-ALK L1196M",
        "id": 7
      },
      {
        "name": "EML4-ALK C1156Y",
        "id": 6
      },
      {
        "name": "EML4-ALK",
        "id": 5
      }
    ],
    "variant_groups": [
      {
        "id": 2,
        "name": "ALK Fusions",
        "description": "ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. ",
        "variants": [
          {
            "id": 7,
            "entrez_name": "ALK",
            "entrez_id": 238,
            "name": "EML4-ALK L1196M",
            "description": "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib."
          },
          {
            "id": 6,
            "entrez_name": "ALK",
            "entrez_id": 238,
            "name": "EML4-ALK C1156Y",
            "description": "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib."
          },
          {
            "id": 5,
            "entrez_name": "ALK",
            "entrez_id": 238,
            "name": "EML4-ALK",
            "description": "The EML4-ALK fusion has been seen in non-small cell lung cancer, and appears to be an alternative mechanism for ALK activation. Cells with this fusion have been shown to be sensitive to the ALK inhibitor crizotinib."
          }
        ]
      },
      {
        "id": 3,
        "name": "Crizotinib Resistance",
        "description": "The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. ",
        "variants": [
          {
            "id": 8,
            "entrez_name": "ALK",
            "entrez_id": 238,
            "name": "F1174L",
            "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells."
          },
          {
            "id": 7,
            "entrez_name": "ALK",
            "entrez_id": 238,
            "name": "EML4-ALK L1196M",
            "description": "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib."
          },
          {
            "id": 6,
            "entrez_name": "ALK",
            "entrez_id": 238,
            "name": "EML4-ALK C1156Y",
            "description": "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib."
          }
        ]
      }
    ],
    "aliases": [
      "CD246",
      "NBLST3"
    ]
  },
  {
    "id": 3,
    "entrez_name": "ARAF",
    "entrez_id": 369,
    "description": "ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.",
    "clinical_description": null,
    "variants": [
      {
        "name": "S214C",
        "id": 10
      }
    ],
    "variant_groups": [],
    "aliases": [
      "A-RAF",
      "ARAF1",
      "PKS2",
      "RAFA1"
    ]
  },
  {
    "id": 8,
    "entrez_name": "CCND1",
    "entrez_id": 595,
    "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.",
    "clinical_description": null,
    "variants": [
      {
        "name": "OVEREXPRESSION",
        "id": 20
      },
      {
        "name": "EXPRESSION",
        "id": 19
      },
      {
        "name": "AMPLIFICATION",
        "id": 18
      }
    ],
    "variant_groups": [],
    "aliases": [
      "BCL1",
      "D11S287E",
      "PRAD1",
      "U21B31"
    ]
  },
  {
    "id": 9,
    "entrez_name": "CCND2",
    "entrez_id": 894,
    "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.",
    "clinical_description": null,
    "variants": [
      {
        "name": "PROMOTER DEMETHYLATION",
        "id": 22
      },
      {
        "name": "OVEREXPRESSION",
        "id": 21
      }
    ],
    "variant_groups": [],
    "aliases": [
      "KIAK0002",
      "MPPH3"
    ]
  },
  {
    "id": 11,
    "entrez_name": "CCNE1",
    "entrez_id": 898,
    "description": "Cyclin E, while currenly not as widely implicated as its cyclin D counterparts, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, have been shown to lead to poorer prognosis in gastic carcinoma, and these measurements are correlated with later stage disease. In lung cancer, neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their more lowly expressed counterparts.",
    "clinical_description": null,
    "variants": [
      {
        "name": "OVEREXPRESSION",
        "id": 24
      }
    ],
    "variant_groups": [],
    "aliases": ["CCNE"]
  },
  {
    "id": 12,
    "entrez_name": "CDK6",
    "entrez_id": 1021,
    "description": "CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.",
    "clinical_description": null,
    "variants": [
      {
        "name": "EXPRESSION",
        "id": 26
      }
    ],
    "variant_groups": [],
    "aliases": [
      "MCPH12",
      "PLSTIRE"
    ]
  },
  {
    "id": 13,
    "entrez_name": "CDK4",
    "entrez_id": 1019,
    "description": "CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.",
    "clinical_description": null,
    "variants": [
      {
        "name": "EXPRESSION",
        "id": 25
      }
    ],
    "variant_groups": [],
    "aliases": [
      "CMM3",
      "PSK-J3"
    ]
  },
  {
    "id": 14,
    "entrez_name": "CDKN2A",
    "entrez_id": 1029,
    "description": "CDKN2A loss has been shown to be a significant event in a number of cancer types. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. One mechanism by which loss of CDKN2A can occur is by hypermethylation of the promoter region for the gene. However, the prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have suggesting poorer prognostic outcome for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.",
    "clinical_description": null,
    "variants": [
      {
        "name": "PROMOTER HYPERMETHYLATION",
        "id": 27
      }
    ],
    "variant_groups": [],
    "aliases": [
      "ARF",
      "CDK4I",
      "CDKN2",
      "CMM2",
      "INK4",
      "INK4A",
      "MLM",
      "MTS-1",
      "MTS1",
      "P14",
      "P14ARF",
      "P16",
      "P16-INK4A",
      "P16INK4",
      "P16INK4A",
      "P19",
      "P19ARF",
      "TP16"
    ]
  },
  {
    "id": 16,
    "entrez_name": "DNAJB1",
    "entrez_id": 3337,
    "description": "DNAJB1 works upstream of MDM2, stabilizing the complex and facilitating p53 turnover. In hepatocellular fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1 to PRKACA is suggested to be a diagnostic marker for this rare subtype of HCC. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity.",
    "clinical_description": null,
    "variants": [
      {
        "name": "DNAJB1-PRKACA",
        "id": 31
      }
    ],
    "variant_groups": [],
    "aliases": [
      "HSPF1",
      "Hdj1",
      "Hsp40",
      "RSPH16B",
      "Sis1"
    ]
  },
  {
    "id": 18,
    "entrez_name": "DNMT3A",
    "entrez_id": 1788,
    "description": "DNMT3A is one of several epigenetic modifiers identified as recurrently mutated in acute myeloid leukemia (AML). DNMT3A mutations are associated with cytogenetically normal AML. In vitro experiments indicate that the R882H mutation acts in a dominant negative manner to disrupt the de novo methyltransferase activity of wildtype homotetramers. AML patient bone marrow harboring R882 mutations were similarly demonstrated to be hypomethylated compared to patients with wildtype DNMT3A. These studies also indicated that non-R882 DNMT3A mutations may act in a functionally distinct manner from R882 mutations. Alternative mechanisms indicate independent prognostic outcomes and treatment protocols may need to be considered for these two classes of DNMT3A mutations.",
    "clinical_description": null,
    "variants": [
      {
        "name": "R882",
        "id": 32
      }
    ],
    "variant_groups": [],
    "aliases": [
      "DNMT3A2",
      "M.HsaIIIA",
      "TBRS"
    ]
  },
  {
    "id": 22,
    "entrez_name": "FGFR2",
    "entrez_id": 2263,
    "description": "The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.",
    "clinical_description": null,
    "variants": [
      {
        "name": "FGFR2-MGEA5",
        "id": 51
      }
    ],
    "variant_groups": [
      {
        "id": 9,
        "name": "FGFR fusions",
        "description": "FGFR fusions have been demonstrated across many cancer types to have oncogenic potential. FGFR2 and FGFR3 have been shown to be fused to many 3' partners, which may act as a vehicle for pathway activation. Treatment of cell lines harboring FGFR2 fusions with pazopanib has shown mild \"anti-tumor\" activities, and both ponatinib and pazopanib have shown efficacy in case studies.  ",
        "variants": [
          {
            "id": 53,
            "entrez_name": "FGFR3",
            "entrez_id": 2261,
            "name": "FGFR3-TACC3",
            "description": "In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts."
          },
          {
            "id": 52,
            "entrez_name": "FGFR3",
            "entrez_id": 2261,
            "name": "FGFR3-BAIAP2L1",
            "description": "In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts."
          },
          {
            "id": 51,
            "entrez_name": "FGFR2",
            "entrez_id": 2263,
            "name": "FGFR2-MGEA5",
            "description": "In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts."
          }
        ]
      }
    ],
    "aliases": [
      "BBDS",
      "BEK",
      "BFR-1",
      "CD332",
      "CEK3",
      "CFD1",
      "ECT1",
      "JWS",
      "K-SAM",
      "KGFR",
      "TK14",
      "TK25"
    ]
  },
  {
    "id": 24,
    "entrez_name": "FLT3",
    "entrez_id": 2322,
    "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.",
    "clinical_description": null,
    "variants": [
      {
        "name": "TKD MUTATIONS",
        "id": 55
      },
      {
        "name": "ITD MUTATIONS",
        "id": 54
      }
    ],
    "variant_groups": [],
    "aliases": [
      "CD135",
      "FLK-2",
      "FLK2",
      "STK1"
    ]
  },
  {
    "id": 25,
    "entrez_name": "GATA2",
    "entrez_id": 2624,
    "description": "GATA2 is a transcription factor involved in stem cell maintenance with key roles in hematopoietic development. GATA2 mutations are associated with a variety of inherited and acquired immune disorders including myelodysplastic syndrome and acute myeloid leukemia. In addition to a role in hematopoiesis, the maintenance GATA2 expression has been implicated as a requirement in KRAS-driven non-small cell lung cancer. Preclinical models have indicated therapeutic benefit from targeting GATA2-mediated pathways in the context of KRAS-driven NSCLC.",
    "clinical_description": null,
    "variants": [
      {
        "name": "EXPRESSION",
        "id": 56
      }
    ],
    "variant_groups": [],
    "aliases": [
      "DCML",
      "IMD21",
      "MONOMAC",
      "NFE1B"
    ]
  },
  {
    "id": 26,
    "entrez_name": "IDH1",
    "entrez_id": 3417,
    "description": "IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.",
    "clinical_description": null,
    "variants": [
      {
        "name": "R132L",
        "id": 60
      },
      {
        "name": "R132H",
        "id": 59
      },
      {
        "name": "R132C",
        "id": 58
      },
      {
        "name": "R132",
        "id": 57
      }
    ],
    "variant_groups": [],
    "aliases": [
      "HEL-216",
      "HEL-S-26",
      "IDCD",
      "IDH",
      "IDP",
      "IDPC",
      "PICD"
    ]
  },
  {
    "id": 27,
    "entrez_name": "IDH2",
    "entrez_id": 3418,
    "description": "IDH2 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. Although IDH2 (R172) mutations are associated with poorer overall prognosis in AML patients, its utility as a prognostic marker in MDS is still under debate. Additionally, IDH2 (R140) has been associated with improved overall survival in AML. IDH2 mutations have been associated with improved prognosis in gliomas.",
    "clinical_description": null,
    "variants": [
      {
        "name": "R172K",
        "id": 62
      },
      {
        "name": "R140Q/L",
        "id": 61
      }
    ],
    "variant_groups": [],
    "aliases": [
      "D2HGA2",
      "ICD-M",
      "IDH",
      "IDHM",
      "IDP",
      "IDPM",
      "mNADP-IDH"
    ]
  },
  {
    "id": 39,
    "entrez_name": "PML",
    "entrez_id": 5371,
    "description": "The PML-RARA fusion is the result of a recurrent, balanced translocation between chromosomes 15 and 17, denoted as t(15;17)(q22;q12), and a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA (all-trans retinoic acid) in APL patients harboring the PML-RARA fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.",
    "clinical_description": null,
    "variants": [
      {
        "name": "PML-RARA",
        "id": 106
      }
    ],
    "variant_groups": [],
    "aliases": [
      "MYL",
      "PP8675",
      "RNF71",
      "TRIM19"
    ]
  },
  {
    "id": 42,
    "entrez_name": "RET",
    "entrez_id": 5979,
    "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistence. No RET-specific agents are currently clinically available but several promiscuous kinase inhibitors that target RET, among others, have been approved for MTC treatment.",
    "clinical_description": null,
    "variants": [
      {
        "name": "M918T",
        "id": 111
      },
      {
        "name": "C634W",
        "id": 110
      }
    ],
    "variant_groups": [
      {
        "id": 14,
        "name": "Motesanib Resistance",
        "description": "RET activation is a common oncogenic marker of medullary thyroid carcinoma. Treatment of these patients with the targeted therapeutic motesanib has shown to be effective. However, the missense mutations C634W and M918T have shown to confer motesanib resistance in cell lines. ",
        "variants": [
          {
            "id": 111,
            "entrez_name": "RET",
            "entrez_id": 5979,
            "name": "M918T",
            "description": "RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis."
          },
          {
            "id": 110,
            "entrez_name": "RET",
            "entrez_id": 5979,
            "name": "C634W",
            "description": "RET C639W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C639W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib."
          }
        ]
      }
    ],
    "aliases": [
      "CDHF12",
      "CDHR16",
      "HSCR1",
      "MEN2A",
      "MEN2B",
      "MTC1",
      "PTC",
      "RET-ELE1",
      "RET51"
    ]
  },
  {
    "id": 43,
    "entrez_name": "RUNX1",
    "entrez_id": 861,
    "description": "A summary for this gene has yet to be developed! Add one now by clicking the \"Edit Gene\" button.",
    "clinical_description": null,
    "variants": [],
    "variant_groups": [],
    "aliases": [
      "AML1",
      "AML1-EVI-1",
      "AMLCR1",
      "CBFA2",
      "EVI-1",
      "PEBP2aB"
    ]
  },
  {
    "id": 45,
    "entrez_name": "TP53",
    "entrez_id": 7157,
    "description": "TP53 mutations are universal across cancer types. Loss of tumor suppressors is most recognized by large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide variants, or missense mutations. These variants are also very broadly distributed throughout the gene, not localizing in any particular hotspot. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) have been found to have prognostic impact on patient outcomes.",
    "clinical_description": null,
    "variants": [
      {
        "name": "V173G/A",
        "id": 121
      },
      {
        "name": "R273H",
        "id": 120
      },
      {
        "name": "R273C",
        "id": 119
      },
      {
        "name": "R249W",
        "id": 118
      },
      {
        "name": "R249T",
        "id": 117
      },
      {
        "name": "R248W",
        "id": 116
      },
      {
        "name": "R248Q",
        "id": 115
      },
      {
        "name": "R175H",
        "id": 114
      }
    ],
    "variant_groups": [],
    "aliases": [
      "BCC7",
      "LFS1",
      "P53",
      "TRP53"
    ]
  },
  {
    "id": 46,
    "entrez_name": "TSC1",
    "entrez_id": 7248,
    "description": "A summary for this gene has yet to be developed! Add one now by clicking the \"Edit Gene\" button.",
    "clinical_description": null,
    "variants": [
      {
        "name": "LOSS-OF-FUNCTION",
        "id": 123
      },
      {
        "name": "FRAMESHIFT TRUNCATION",
        "id": 122
      }
    ],
    "variant_groups": [
      {
        "id": 15,
        "name": "TSC Loss",
        "description": "Inactivating events in TSC1 and TSC2 have been observed in a number of cancer types. Cell lines and case studies have shown that in the loss of TSC, the mTOR inhibitor everolimus has seen significant anti-tumorigenic activity. ",
        "variants": [
          {
            "id": 124,
            "entrez_name": "TSC2",
            "entrez_id": 7249,
            "name": "LOSS-OF-FUNCTION",
            "description": "In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells."
          },
          {
            "id": 123,
            "entrez_name": "TSC1",
            "entrez_id": 7248,
            "name": "LOSS-OF-FUNCTION",
            "description": "In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells."
          },
          {
            "id": 122,
            "entrez_name": "TSC1",
            "entrez_id": 7248,
            "name": "FRAMESHIFT TRUNCATION",
            "description": "In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells."
          }
        ]
      }
    ],
    "aliases": [
      "LAM",
      "TSC"
    ]
  },
  {
    "id": 47,
    "entrez_name": "TSC2",
    "entrez_id": 7249,
    "description": "A summary for this gene has yet to be developed! Add one now by clicking the \"Edit Gene\" button.",
    "clinical_description": null,
    "variants": [
      {
        "name": "LOSS-OF-FUNCTION",
        "id": 124
      }
    ],
    "variant_groups": [
      {
        "id": 15,
        "name": "TSC Loss",
        "description": "Inactivating events in TSC1 and TSC2 have been observed in a number of cancer types. Cell lines and case studies have shown that in the loss of TSC, the mTOR inhibitor everolimus has seen significant anti-tumorigenic activity. ",
        "variants": [
          {
            "id": 124,
            "entrez_name": "TSC2",
            "entrez_id": 7249,
            "name": "LOSS-OF-FUNCTION",
            "description": "In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells."
          },
          {
            "id": 123,
            "entrez_name": "TSC1",
            "entrez_id": 7248,
            "name": "LOSS-OF-FUNCTION",
            "description": "In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells."
          },
          {
            "id": 122,
            "entrez_name": "TSC1",
            "entrez_id": 7248,
            "name": "FRAMESHIFT TRUNCATION",
            "description": "In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells."
          }
        ]
      }
    ],
    "aliases": [
      "LAM",
      "PPP1R160",
      "TSC4"
    ]
  },
  {
    "id": 49,
    "entrez_name": "WT1",
    "entrez_id": 7490,
    "description": "WT1 is a tumor suppressor gene associated with the development of Wilms' Tumor, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.",
    "clinical_description": null,
    "variants": [
      {
        "name": "EXON 9 MUTATIONS",
        "id": 128
      },
      {
        "name": "EXON 7 MUTATIONS",
        "id": 127
      }
    ],
    "variant_groups": [],
    "aliases": [
      "AWT1",
      "EWS-WT1",
      "GUD",
      "NPHS4",
      "WAGR",
      "WIT-2",
      "WT33"
    ]
  },
  {
    "id": 34,
    "entrez_name": "MGMT",
    "entrez_id": 4255,
    "description": "A summary for this gene has yet to be developed! Add one now by clicking the \"Edit Gene\" button.",
    "clinical_description": null,
    "variants": [
      {
        "name": "PROMOTER METHYLATION",
        "id": 84
      }
    ],
    "variant_groups": [],
    "aliases": []
  },
  {
    "id": 10,
    "entrez_name": "CCND3",
    "entrez_id": 896,
    "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. Cyclin D3 loss has been reported in T-ALL, a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. In a mouse study, the targeted therapeutic palbociclib significantly increased the median survival of the cyclin D3 knockouts.",
    "clinical_description": null,
    "variants": [
      {
        "name": "LOSS",
        "id": 23
      }
    ],
    "variant_groups": [],
    "aliases": []
  },
  {
    "id": 32,
    "entrez_name": "MEF2D",
    "entrez_id": 4209,
    "description": "A summary for this gene has yet to be developed! Add one now by clicking the \"Edit Gene\" button.",
    "clinical_description": null,
    "variants": [
      {
        "name": "MEF2D-CSF1R",
        "id": 83
      }
    ],
    "variant_groups": [],
    "aliases": []
  }
]
